Incyte Corporation Faces Investigation Amid Drug Development Setbacks
Incyte Corporation faces scrutiny as Levi & Korsinsky LLP investigates potential federal securities law violations following the company’s pause in clinical trials and drug discontinuations. After announcing concerning toxicology findings, Incyte’s stock plummeted by 12%, raising investor concerns. Shareholders affected by these developments are encouraged to reach out for legal advice as the investigation unfolds, highlighting the risks in biopharmaceutical investments.
Novartis Leading Race to Acquire German Cancer Drug Maker MorphoSys
Novartis is reportedly leading the race to acquire German cancer drug maker MorphoSys, according to a recent report by Reuters. The news has caused a spike in MorphoSys’ share price, indicating significant market interest in the potential acquisition. Earlier this…